A phase III study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP)

Trial Profile

A phase III study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP)

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2017 According to Clementia Pharmaceuticals media release, the company plans to initiate this study in later 2017
    • 14 Oct 2016 According to Clementia Pharmaceuticals media release, the company plans to initiate this study in 2017
    • 27 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top